Modern paradigms for prostate cancer detection and management. Issue 8 (2nd October 2022)

• Record Type: Journal Article
• Authors: Williams, Isabella SC; McVey, Aoife; Perera, Sachin; O'Brien, Jonathan S; Kostos, Louise; Chen, Kenneth; Siva, Shankar; Azad, Arun A; Murphy, Declan G; Kasivisvanathan, Veeru; Lawrentschuk, Nathan; Frydenberg, Mark
• Is Part Of: Medical journal of Australia. Volume 217:Issue 8(2022)
• Page Start: 424
• Page End: 433
• Publication Date: 2022-10-02
• Subjects: Prostatic neoplasms -- Prostate -- Chemotherapy -- Radiation oncology -- Radiotherapy -- Surgical oncology; Medicine -- Periodicals; Medicine; Médecine -- Périodiques; Medicine; Periodical; Periodicals; Electronic journals; 610
• DOI: 10.5694/mja2.51722
• Languages: English
• ISSNs: 0025-729X

Abstract

Summary: Early detection and management of prostate cancer has evolved over the past decade, with a focus now on harm minimisation and reducing overdiagnosis and overtreatment, given the proven improvements in survival from randomised controlled trials. Multiparametric magnetic resonance imaging (mpMRI) is now an important aspect of the diagnostic pathway in prostate cancer, improving the detection of clinically significant prostate cancer, enabling accurate localisation of appropriate sites to biopsy, and reducing unnecessary biopsies in most patients with normal magnetic resonance imaging scans. Biopsies are now performed transperineally, substantially reducing the risk of post‐procedure sepsis. Australian‐led research has shown that prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has superior accuracy in the staging of prostate cancer than conventional imaging (CT and whole‐body bone scan). Localised prostate cancer that is low risk (International Society for Urological Pathology [ISUP] grade 1, Gleason score 3 + 3 = 6; and ISUP grade group 2, Gleason score 3 + 4 = 7 with less than 10% pattern 4) can be offered active surveillance, reducing harms from overtreatment. Prostatectomy and definitive radiation remain the gold standard for localised intermediate and high risk disease. However, focal therapy is an emerging experimental treatment modality in Australia in carefully selected patients. The management of advanced prostate cancer treatment has evolved to now include several novel agents both in the metastatic hormone‐sensitive and castration‐resistant disease settings. Multimodal therapy with androgen deprivation therapy, additional systemic therapy and radiotherapy are often recommended. PSMA‐based radioligand therapy has emerged as a treatment option for metastatic castration‐resistant prostate cancer and is currently being evaluated in earlier disease states.